Broad spectrum shigella subunit vaccine based on conserved proteins
Active Project Grant Awarded Last action
- Award ID
- R01AI161839
- Recipient
-
University Of Maryland, Baltimore UEI Z9CRZKD42ZT1 Part of University System Of Maryland
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,840,404
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 95% complete
- Originally
- Funding
-
- $6,303,994.00 Federal
- $536,410.00 Non-federal
- Place of performance
- Baltimore, MD 21201, USA
Award details come from USAspending.gov.
Description
- Abstract
- Shigella SPP. Are a major global cause of diarrhea and dysentery. Children 2-5 years of age in low- and middle- income countries are the most affected. Mortality is second only to rotavirus among diarrheal diseases in young children, and repeated bouts of disease cause lifelong disability. In industrialized nations, shigella outbreaks have occurred in day care centers and medical institutions. Shigella SPP. Rapidly acquire genetic elements that confer antimicrobial resistance. A safe, effective, and affordable vaccine could make a major public health impact, yet none is currently approved. Candidates based on the shigella-o-antigen are in clinical development. However, that approach is impractical and costly, requiring multiple vaccines to prevent disease caused by shigella strains with different o antigens. This proposal seeks to develop a safe, practical, and effective broad- spectrum shigella vaccine based on highly conserved shigella type III secretion system (ttss) proteins, invasion plasmid antigen (IPA) b, ipah, and the virulence antigen virg (icsa). Our laboratory was the first to report the high immunogenic and broad protective capacity of shigella ipab in mice, and the association of ipab- and virg- serum IGG (IGG1) levels with clinical protection against shigellosis in humans. Preliminary data in this application demonstrate that virg also elicits potent and protective immunity. In addition, we have found that adults living in endemic regions who acquire natural immunity to shigella have high levels of ipab-, virg-, and ipah- serum antibodies. Maternal IGG against these proteins are more efficiently transferred to infants through the placenta as compared to IGG against the o-polysaccharide. High levels of antibodies are also present in breast milk. This robust maternally-derived immunity is consistent with the low incidence of infection at
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $528,481 | $0 | |
| Amendment | $528,481 | $0 | |
| Amendment | $52,615 | $0 | |
| Amendment | $52,615 | $0 | |
| Amendment | $473,548 | $0 | |
| Amendment | $473,548 | $0 | |
| Amendment | $473,548 | $0 | |
| Amendment | $531,262 | $0 | |
| Amendment | $531,262 | $0 | |
| Amendment | $531,262 | $0 | |
| Amendment | $531,262 | $0 | |
| Amendment | $523,290 | $0 | |
| Amendment | $536,410 | $0 | |
| Original award | $536,410 | $536,410 |
Show all 15
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Vaxcyte, Inc. | $98,628 | |
| Vaxcyte, Inc. | $98,628 |
Quick answers
Who received award R01AI161839?
R01AI161839 was awarded to University Of Maryland, Baltimore by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on February 4, 2021.
How much is award R01AI161839 worth?
$6,840,404 has been obligated on R01AI161839: $6,303,994 in federal funding and $536,410 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award